GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » SciClone Pharmaceuticals Inc (NAS:SCLN) » Definitions » Shiller PE Ratio

SciClone Pharmaceuticals (SciClone Pharmaceuticals) Shiller PE Ratio : 30.97 (As of Apr. 25, 2024)


View and export this data going back to 1992. Start your Free Trial

What is SciClone Pharmaceuticals Shiller PE Ratio?

As of today (2024-04-25), SciClone Pharmaceuticals's current share price is $11.15. SciClone Pharmaceuticals's E10 for the quarter that ended in Jun. 2017 was $0.36. SciClone Pharmaceuticals's Shiller PE Ratio for today is 30.97.

The historical rank and industry rank for SciClone Pharmaceuticals's Shiller PE Ratio or its related term are showing as below:

SCLN's Shiller PE Ratio is not ranked *
in the Drug Manufacturers industry.
Industry Median: 24.47
* Ranked among companies with meaningful Shiller PE Ratio only.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

SciClone Pharmaceuticals's adjusted earnings per share data for the three months ended in Jun. 2017 was $0.230. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is $0.36 for the trailing ten years ended in Jun. 2017.

Shiller PE for Stocks: The True Measure of Stock Valuation


SciClone Pharmaceuticals Shiller PE Ratio Historical Data

The historical data trend for SciClone Pharmaceuticals's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SciClone Pharmaceuticals Shiller PE Ratio Chart

SciClone Pharmaceuticals Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 176.25 - 57.21 39.12 36.16

SciClone Pharmaceuticals Quarterly Data
Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 50.52 36.31 36.16 29.49 30.23

Competitive Comparison of SciClone Pharmaceuticals's Shiller PE Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, SciClone Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SciClone Pharmaceuticals's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, SciClone Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where SciClone Pharmaceuticals's Shiller PE Ratio falls into.



SciClone Pharmaceuticals Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

SciClone Pharmaceuticals's Shiller PE Ratio for today is calculated as

Shiller PE Ratio=Share Price/ E10
=11.15/0.36
=30.97

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SciClone Pharmaceuticals's E10 for the quarter that ended in Jun. 2017 is calculated as:

For example, SciClone Pharmaceuticals's adjusted earnings per share data for the three months ended in Jun. 2017 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Jun. 2017 (Change)*Current CPI (Jun. 2017)
=0.23/103.3491*103.3491
=0.230

Current CPI (Jun. 2017) = 103.3491.

SciClone Pharmaceuticals Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
200709 -0.070 87.964 -0.082
200712 -0.080 88.616 -0.093
200803 -0.120 90.090 -0.138
200806 -0.010 92.320 -0.011
200809 0.020 92.307 0.022
200812 -0.070 88.697 -0.082
200903 0.000 89.744 0.000
200906 0.160 91.003 0.182
200909 0.040 91.120 0.045
200912 0.050 91.111 0.057
201003 0.090 91.821 0.101
201006 0.110 91.962 0.124
201009 0.160 92.162 0.179
201012 0.080 92.474 0.089
201103 0.080 94.283 0.088
201106 0.030 95.235 0.033
201109 0.180 95.727 0.194
201112 0.200 95.213 0.217
201203 0.160 96.783 0.171
201206 0.190 96.819 0.203
201209 -0.230 97.633 -0.243
201212 0.030 96.871 0.032
201303 0.080 98.209 0.084
201306 -0.040 98.518 -0.042
201309 0.160 98.790 0.167
201312 0.000 98.326 0.000
201403 0.080 99.695 0.083
201406 0.180 100.560 0.185
201409 0.150 100.428 0.154
201412 0.070 99.070 0.073
201503 0.170 99.621 0.176
201506 -0.080 100.684 -0.082
201509 0.230 100.392 0.237
201512 0.240 99.792 0.249
201603 0.150 100.470 0.154
201606 0.120 101.688 0.122
201609 0.190 101.861 0.193
201612 0.120 101.863 0.122
201703 0.280 102.862 0.281
201706 0.230 103.349 0.230

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


SciClone Pharmaceuticals  (NAS:SCLN) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


SciClone Pharmaceuticals Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of SciClone Pharmaceuticals's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


SciClone Pharmaceuticals (SciClone Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
SciClone Pharmaceuticals Inc is a specialty pharmaceutical company with a substantial commercial business in China and a product portfolio of therapies for oncology, infectious diseases and cardiovascular disorders.
Executives
Richard J Hawkins director 950 TOWER LANE, SUITE 900, FOSTER CITY CA 94404-2125
Nancy T Chang director 101 WESTCOTT, SUITE 603, HOUSTON TX 77007
Raymond Anthony Low director, officer: VP, Finance & Controller 25 SHADOW TREE CT, DANVILLE CA 94506
Wilson Wai-shun Cheung officer: CFO & Senior VP, Finance SCICLONE PHARMACEUTICALS, INC., 950 TOWER LANE, SUITE 900, FOSTER CITY CA 94404
Jon S Saxe director FIRST HORIZON PHARMACEUTICAL CORP, 660 HEMBREE PKWY STE 106, ROSWELL GA 30076
Anthony Gregg Lapointe director PO BOX 83216, GAITHERSBURG MD 20883-3216
Robert King officer: SVP of Prod. Dev/Supply Chain 950 TOWER LANE, SUITE 900, FOSTER CITY CA 94404
Winnie Wing-kei Tso other: VP, Finance and Controller 950 TOWER LANE, SUITE 900, FOSTER CITY CA 94404
Stephanie Wong officer: VP, Finance and Controller 343 OYSTER POINT BLVD #200, SOUTH SAN FRANCISCO CA 94080
Gary Titus officer: Senior VP Finance & CFO SCICLONE PHARMACEUTICALS, INC., 950 TOWER LANE, SUITE 900, FOSTER CITY CA 94404-2125
Peter Barrett director C/O ALNYLAM PHARMACEUTICALS, INC., 300 THIRD STREET, CAMBRIDGE MA 02142
Spa Essetifin 10 percent owner VIA SUDAFRICA 20, ROME L6 00144
Paolo Cavazza 10 percent owner VIA TESSERETE, 10, LUGANO V8 V8
Farmaceutica Lda Defiante 10 percent owner RUA DOS FERREIROS,260, FUNCHAL MADEIRA S1 9000-082
Dean S Woodman director 233 MOCKINGBIRD TRAIL, PALM BEACH FL 33480